Correlation Between Pyxis Oncology and Effector Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pyxis Oncology and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pyxis Oncology and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pyxis Oncology and Effector Therapeutics, you can compare the effects of market volatilities on Pyxis Oncology and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pyxis Oncology with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pyxis Oncology and Effector Therapeutics.

Diversification Opportunities for Pyxis Oncology and Effector Therapeutics

PyxisEffectorDiversified AwayPyxisEffectorDiversified Away100%
0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Pyxis and Effector is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Pyxis Oncology and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Pyxis Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pyxis Oncology are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Pyxis Oncology i.e., Pyxis Oncology and Effector Therapeutics go up and down completely randomly.

Pair Corralation between Pyxis Oncology and Effector Therapeutics

If you would invest (100.00) in Effector Therapeutics on December 11, 2024 and sell it today you would earn a total of  100.00  from holding Effector Therapeutics or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Pyxis Oncology  vs.  Effector Therapeutics

 Performance 
JavaScript chart by amCharts 3.21.15Dec2025Feb 102030405060
JavaScript chart by amCharts 3.21.15PYXS EFTR
       Timeline  
Pyxis Oncology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pyxis Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
JavaScript chart by amCharts 3.21.15JanFebMarFebMar1.11.21.31.41.51.61.71.8
Effector Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Effector Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Effector Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pyxis Oncology and Effector Therapeutics Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-6.72-5.03-3.34-1.66-0.02391.392.824.255.697.12 0.0050.0100.0150.0200.025
JavaScript chart by amCharts 3.21.15PYXS EFTR
       Returns  

Pair Trading with Pyxis Oncology and Effector Therapeutics

The main advantage of trading using opposite Pyxis Oncology and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pyxis Oncology position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.
The idea behind Pyxis Oncology and Effector Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance